. "Sp\u00E1nkov\u00E1 apnoe a kardiovaskul\u00E1rn\u00ED onemocn\u011Bn\u00ED"@cs . . "RIV/65269705:_____/13:#0002145" . . "15" . . . "Kardiologick\u00E1 Revue" . . "Sp\u00E1nkov\u00E1 apnoe a kardiovaskul\u00E1rn\u00ED onemocn\u011Bn\u00ED" . . . "15"^^ . "Mor\u00E1\u0148, Miroslav" . "CZ - \u010Cesk\u00E1 republika" . "Ludka, Ond\u0159ej" . . . . "\u0160pinar, Jind\u0159ich" . . "Sleep apnea and cardiovascular disease"@en . . "7"^^ . "RIV/65269705:_____/13:#0002145!RIV14-MZ0-65269705" . . . "Sleep apnea and cardiovascular disease. The most common breathing disorders during sleep include sleep apnea, which can be divided into obstructive and central. While central sleep apnea occurs most frequently in patients with heart failure, obstructive is more common in patients with hypertension, arrhythmias, stroke ar coronary artery disease. Epidemioiogical, clinical and therapeutic studies provided convincing evidence of an association between obstructive sleep apnea and increased risk of cardiovascular morbidity and modality. Obstructive sleep apnea is also a modifiable risk factor when treatment with continuous non-invasive positive pressure ventilation might lead to reduction of early signs of endothelial dysfunction and atherosclerosis, kmering of blood pressure and nonfatal cardiovascular events and mortaiity associated with cardiovascular disease. However, up to 85 % of patients with clinically significant and treatable obstruct\u00EDve sleep apnea were never diagnosed and therefore not treated. It is therefore important to develop a diagnostic strategy oriented towards the detection of o obstructive sleep apnea in patients with cardiovascular disease.."@en . "2" . . "106773" . "3"^^ . "Mezi nej\u010Dast\u011Bj\u0161\u00ED poruchy d\u00FDch\u00E1n\u00ED ve sp\u00E1nku pat\u0159\u00ED sp\u00E1nkov\u00E1 apnoe, kterou m\u016F\u017Eeme d\u00E1le d\u011Blit na obstruk\u010Dn\u00ED a centr\u00E1ln\u00ED. Zat\u00EDmco centr\u00E1ln\u00ED sp\u00E1nkov\u00E1 apnoe se vyskytuje nej\u010Dast\u011Bji u pacient\u016F se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, obstruk\u010Dn\u00ED je \u010Dast\u011Bj\u0161\u00ED u pacient\u016F s hypertenz\u00ED, arytmiemi, c\u00E9vn\u00ED mozkovou p\u0159\u00EDhodou \u010Di s onemocn\u011Bn\u00EDm koron\u00E1rn\u00EDch tepen. Epidemiologick\u00E9, klinick\u00E9 a terapeutick\u00E9 studie p\u0159inesly p\u0159esv\u011Bd\u010Div\u00E9 d\u016Fkazy o souvislostech mezi obstruk\u010Dn\u00ED sp\u00E1nkovou apno\u00ED a vzr\u016Fstaj\u00EDc\u00EDm rizikem kardiovaskul\u00E1rn\u00ED morbidity a modality. Obstruk\u010Dn\u00ED sp\u00E1nkov\u00E1 apnoe je ale z\u00E1rove\u0148 modifikovateln\u00FDm rizikov\u00FDm faktorem, kdy m\u016F\u017Ee l\u00E9\u010Dba pomoc\u00ED neinvazivn\u00ED kontinu\u00E1ln\u00ED pozitivn\u00ED p\u0159etlakov\u00E9 ventilace v\u00E9st nap\u0159. k redukci \u010Dasn\u00FDch zn\u00E1mek endoteli\u00E1ln\u00ED dysfunkce a ateroskler\u00F3zy, ke sn\u00ED\u017Een\u00ED krevn\u00EDho tlaku, nefat\u00E1ln\u00EDch kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod a modality souvisej\u00EDc\u00ED s kardiovaskul\u00E1rn\u00EDmi onemocn\u011Bn\u00EDmi. P\u0159itom a\u017E 85% pacient\u016F s klinicky signifikantn\u00ED a l\u00E9\u010Ditelnou obstruk\u010Dn\u00ED sp\u00E1nkovou apno\u00ED nikdy nebylo diagnostikov\u00E1no, a tud\u00ED\u017E ani l\u00E9\u010Deno. Je tedy d\u016Fle\u017Eit\u00E9 vytvo\u0159it diagnostickou strategii orientovanou na zji\u0161\u0165oov\u00E1n\u00ED p\u0159\u00EDtomnosti obstruk\u010Dn\u00ED sp\u00E1nkov\u00E9 apnoe u pacient\u016F s kardiovaskul\u00E1rn\u00EDmi onemocn\u011Bn\u00EDmi."@cs . . "Sleep apnea and cardiovascular disease"@en . . "[4B8DEB544BA9]" . "Sp\u00E1nkov\u00E1 apnoe a kardiovaskul\u00E1rn\u00ED onemocn\u011Bn\u00ED" . "Mezi nej\u010Dast\u011Bj\u0161\u00ED poruchy d\u00FDch\u00E1n\u00ED ve sp\u00E1nku pat\u0159\u00ED sp\u00E1nkov\u00E1 apnoe, kterou m\u016F\u017Eeme d\u00E1le d\u011Blit na obstruk\u010Dn\u00ED a centr\u00E1ln\u00ED. Zat\u00EDmco centr\u00E1ln\u00ED sp\u00E1nkov\u00E1 apnoe se vyskytuje nej\u010Dast\u011Bji u pacient\u016F se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, obstruk\u010Dn\u00ED je \u010Dast\u011Bj\u0161\u00ED u pacient\u016F s hypertenz\u00ED, arytmiemi, c\u00E9vn\u00ED mozkovou p\u0159\u00EDhodou \u010Di s onemocn\u011Bn\u00EDm koron\u00E1rn\u00EDch tepen. Epidemiologick\u00E9, klinick\u00E9 a terapeutick\u00E9 studie p\u0159inesly p\u0159esv\u011Bd\u010Div\u00E9 d\u016Fkazy o souvislostech mezi obstruk\u010Dn\u00ED sp\u00E1nkovou apno\u00ED a vzr\u016Fstaj\u00EDc\u00EDm rizikem kardiovaskul\u00E1rn\u00ED morbidity a modality. Obstruk\u010Dn\u00ED sp\u00E1nkov\u00E1 apnoe je ale z\u00E1rove\u0148 modifikovateln\u00FDm rizikov\u00FDm faktorem, kdy m\u016F\u017Ee l\u00E9\u010Dba pomoc\u00ED neinvazivn\u00ED kontinu\u00E1ln\u00ED pozitivn\u00ED p\u0159etlakov\u00E9 ventilace v\u00E9st nap\u0159. k redukci \u010Dasn\u00FDch zn\u00E1mek endoteli\u00E1ln\u00ED dysfunkce a ateroskler\u00F3zy, ke sn\u00ED\u017Een\u00ED krevn\u00EDho tlaku, nefat\u00E1ln\u00EDch kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod a modality souvisej\u00EDc\u00ED s kardiovaskul\u00E1rn\u00EDmi onemocn\u011Bn\u00EDmi. P\u0159itom a\u017E 85% pacient\u016F s klinicky signifikantn\u00ED a l\u00E9\u010Ditelnou obstruk\u010Dn\u00ED sp\u00E1nkovou apno\u00ED nikdy nebylo diagnostikov\u00E1no, a tud\u00ED\u017E ani l\u00E9\u010Deno. Je tedy d\u016Fle\u017Eit\u00E9 vytvo\u0159it diagnostickou strategii orientovanou na zji\u0161\u0165oov\u00E1n\u00ED p\u0159\u00EDtomnosti obstruk\u010Dn\u00ED sp\u00E1nkov\u00E9 apnoe u pacient\u016F s kardiovaskul\u00E1rn\u00EDmi onemocn\u011Bn\u00EDmi." . "I, P(ED1.100/02/0123), P(NT11401)" . . "obstructive sleep apnea; central sleep apnea; morbidity; mortality; cardiovascular disease"@en . . . "Sp\u00E1nkov\u00E1 apnoe a kardiovaskul\u00E1rn\u00ED onemocn\u011Bn\u00ED"@cs . . "1212-4540" .